Driven by chemistry but increasingly guided by pharmacology and the clinica
l sciences, drug research has contributed more to the progress of medicine
during the past century than any other scientific factor. The advent of mol
ecular biology and, in particular, of genomic sciences is having a deep imp
act on drug discovery. Recombinant proteins and monoclonal antibodies have
greatly enriched our therapeutic armamentarium. Genome sciences, combined w
ith bioinformatic tools, allow us to dissect the genetic basis of multifact
orial diseases and to determine the most suitable points of attack for futu
re medicines, thereby increasing the number of treatment options. The drama
tic increase in the complexity of drug research is enforcing changes in the
institutional basis of this interdisciplinary endeavor. The biotech indust
ry is establishing itself as the discovery arm of the pharmaceutical indust
ry. In bridging the gap between academia and Large pharmaceutical companies
, the biotech firms have been effective instruments of technology transfer.